Shell Stocks; Reverse Mergers; Acquisitions; Zombies; Greys; & All "Other" Plays

[Potse]

VODG(.135)...corporate activity expected to increase.....

I'm expecting to see a significant increase in corporate activity and a more robust approach to investor relations at VODG following a successful closing on the proposed $1.7 million financing. As per the recent press release and 8-K filing, the company should regain SEC compliance and there will be changes/additions to management and the Board of Directors.

The person/entity that is providing the $1.7M financing is prepared (if necessary) to loan/invest an additional $6.6M in VODG. But with a new CFO expected to officially come on board, I wouldn't be surprised if VODG starts attracting additional financing(s) from third parties.

It appears the proposed activity/transactions outlined in the release/filing have been under development for at least 8+ months, since the VODG CEO registered the website for the company's new subsidiary (Halo Cell Sciences) back in August 2016. The website came online last week with the "Website Coming Soon" sign.....

http://www.halocellsciences.com/

Vitro Biopharma Receives Funding to Expand its Stem Cell Therapies

Golden, Colorado—March 29, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the completion of a bridge loan in the amount of $125,000 and the execution of a Memorandum of Understanding (“MOU”) outlining the terms of a larger, subsequent financing to provide a total of not less than $1.7 million. Completion of the subsequent larger financing through the execution of a definitive agreement would initiate the establishment of a stem cell center of excellence in the Grand Cayman Islands. The bridge loan is provided by the Caribbean GC Development Fund, Ltd; a Cayman-based company specifically organized to fund stem cell projects in Grand Cayman.

“The benefits of the award-winning stem cell technology that Vitro Biopharma brings combined with the pristine and affluent environment of Grand Cayman and the availability of highly trained professional staff makes for a prolific, highly professional and cutting edge organization that directly addresses the immediate needs for those who are requiring the very best care available”, commented, Mr. William W. Becker, CEO of the Caribbean GC Development Fund, Ltd. Vitro Biopharma has recently established Halo Cell Sciences, Ltd.(“HCS”) as a wholly owned subsidiary incorporated under the laws of the Grand Cayman Islands. HCS will provide the platform and benefit to Vitro Biopharma in expanding its focus to include the application of its technology, products & services for various unmet medical needs in regenerative medicine. Stem cell therapy is evolving through early stage clinical trials as a therapeutic option for treatment of skeletal-muscular conditions such as osteoarthritis, various neurological conditions and cardiovascular disease.

Dr. Jim Musick, Ph.D., President and CEO of Vitro Biopharma said, “We continue to see growth of our product and service revenue as we move towards the achievement of profitability. We plan to use our increased resources to gain SEC compliance, expand operations and to access new distribution channels & capital. Our team has recently been expanded to include the expert services of John R. Evans as CFO. John has extensive financial experience as CFO/CEO of start-ups & large capital firms with $250 million in revenues. John’s expertise also includes raising significant capital, numerous M&A transactions, several successful IP licenses and strategic business development. I value his services and look forward to enhanced operational efficiency and expanded growth due to his addition to our team. Together with our advanced, propriety stem cell technology, products and services, we are well-positioned to capitalize on the growing global market for stem cell-based regenerative medicine. As is the case with our existing Fortune 100 clients; the Caribbean GC Development Fund chose us because of our highest of quality standards and technological advancements. Our expanding array of technology and services affords stem cell-based regenerative medicine approaches providing new avenues of treatment to several conditions that have previously been treated only at a symptomatic level.”

John R Evans said, “I am pleased to be on the team with Jim who is taking his leading edge research from the lab into practical applications that are going to drive the corporate revenue growth for years ahead.”

https://www.sec.gov/Archives/edgar/data/793171/000101103417000023/vitro_99ez2.htm